BDMD vs NVCR vs ARAY vs AEYE vs ELMD

For growth investors, Baird Medical Investment Holdings Limited (BDMD) is the stronger pick with 17.

7% revenue growth year-over-year, versus 2. 7% for Accuray Incorporated (ARAY). Baird Medical Investment Holdings Limited (BDMD) offers the better valuation at 3. 8x trailing P/E, making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Baird Medical Investment Holdings Limited (BDMD) is the cheapest at 3.

8x versus Electromed, Inc. at 31. 2x.

Over the past 5 years, Electromed, Inc.

(ELMD) delivered a total return of +178. 1%, compared to -93. 9% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: ELMD returned +482. 6% versus ARAY's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Electromed, Inc.

(ELMD) is the lower-risk stock at 1. 03β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately 135% more volatile than ELMD relative to the S&P 500. On balance sheet safety, Electromed, Inc. (ELMD) carries a lower debt/equity ratio of 0% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Baird Medical Investment Holdings Limited (BDMD) is pulling ahead at 17.

7% versus 2. 7% for Accuray Incorporated (ARAY). On earnings-per-share growth, the picture is similar: Accuray Incorporated grew EPS 90. 3% year-over-year, compared to 19. 5% for Baird Medical Investment Holdings Limited. Over a 3-year CAGR, ELMD leads at 15. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Baird Medical Investment Holdings Limited (BDMD) is the more profitable company, earning 33.

6% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 33. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDMD leads at 41. 4% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — BDMD leads at 88. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Electromed, Inc.

(ELMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +482. 6% 10Y return). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ELMD: +482. 6%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BDMD (Healthcare) and NVCR (Healthcare) and ARAY (Healthcare) and AEYE (Technology) and ELMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BDMD is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; ARAY is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; ELMD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.